- Home
- MUA vs RIGL Comparison
MUA vs RIGL Comparison
Compare MUA & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MUA
- RIGL
- Stock Information
- Founded
- MUA 1993
- RIGL 1996
- Country
- MUA United States
- RIGL United States
- Employees
- MUA N/A
- RIGL N/A
- Industry
- MUA Investment Bankers/Brokers/Service
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- MUA Finance
- RIGL Health Care
- Exchange
- MUA Nasdaq
- RIGL Nasdaq
- Market Cap
- MUA 424.8M
- RIGL 366.5M
- IPO Year
- MUA N/A
- RIGL 2000
- Fundamental
- Price
- MUA $10.93
- RIGL $17.15
- Analyst Decision
- MUA
- RIGL Buy
- Analyst Count
- MUA 0
- RIGL 5
- Target Price
- MUA N/A
- RIGL $36.80
- AVG Volume (30 Days)
- MUA 92.6K
- RIGL 253.6K
- Earning Date
- MUA 01-01-0001
- RIGL 03-04-2025
- Dividend Yield
- MUA 4.84%
- RIGL N/A
- EPS Growth
- MUA N/A
- RIGL N/A
- EPS
- MUA N/A
- RIGL 0.99
- Revenue
- MUA N/A
- RIGL $179,278,000.00
- Revenue This Year
- MUA N/A
- RIGL $14.19
- Revenue Next Year
- MUA N/A
- RIGL $13.10
- P/E Ratio
- MUA N/A
- RIGL $17.17
- Revenue Growth
- MUA N/A
- RIGL 54.71
- 52 Week Low
- MUA $8.61
- RIGL $7.48
- 52 Week High
- MUA $11.43
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- MUA 50.24
- RIGL 32.74
- Support Level
- MUA $10.72
- RIGL $19.81
- Resistance Level
- MUA $11.04
- RIGL $19.97
- Average True Range (ATR)
- MUA 0.11
- RIGL 1.04
- MACD
- MUA 0.02
- RIGL -0.31
- Stochastic Oscillator
- MUA 60.00
- RIGL 5.83
About MUA Blackrock MuniAssets Fund Inc
Blackrock Muniassets Fund Inc is a closed-end fund. Its objective is to provide high current income exempt from U.S. federal income taxes by investing in a portfolio of medium- to lower-grade or unrated municipal obligations.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.